Caring for underserved cancer patient populations
ESMO continues its commitment to gender-diverse and sex-specific oncology to address the growing need to close knowledge gaps among oncologists
Research offers novel insights to refine first-line treatment in GEP-NETs
Data from new clinical trials reported positive results of radioligand therapy over everolimus and sunitinib, and explore the combination of everolimus and somatostatin analogues
AI is transforming cancer diagnosis, but systemic barriers still hold it back
A new ESMO systematic review maps AI’s growing role in pathology and oncology, as well as challenges in its implementation due to infrastructure, regulatory framework and human factors
What is the role of adjuvant immunotherapy in contemporary melanoma care?
Adjuvant immunotherapy is still actual despite heterogeneity on its accessibility in Europe and fast advances in neoadjuvant immunotherapy
Peters: “Leadership can be isolating, especially for women”
In a video series produced by the ESMO Women for Oncology, Solange Peters reflects on her career and the leadership challenges she has faced
AI applications in oncology go beyond clinical practice
While many models and tools are designed to support clinical decision-making, AI is already serving cancer research for background tasks, with some potential to educate patients too
An ESMO roadmap for implementing molecular tumour boards
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice
Perioperative durvalumab led to encouraging survival data in resectable NSCLC
An improvement was observed when immunotherapy was added to neoadjuvant chemotherapy, but further data are needed to confirm the survival benefit
Overall survival benefit achieved with amivantamab plus lazertinib in advanced EGFR-mutated NSCLC
Final results from the MARIPOSA trial provide further supporting evidence to the first-line treatment combination
Drug de-escalation in lung cancer: are we nearly there yet?
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability